Harvard Bioscience (HBIO) PT Raised to $7.50 at Benchmark on Q2 Beat and Raise
Tweet Send to a Friend
Benchmark analyst Bruce Jackson raised the price target on Harvard Bioscience Inc. (NASDAQ: HBIO) to $7.50 (from $6.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
